Pulike Biological Engineering Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wei Hu

İcra Kurulu Başkanı

CN¥2.6m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	13.7yrs
CEO sahipliği	1.2%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	7.5yrs

Son yönetim güncellemeleri

Recent updates

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Sep 04

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28

CEO

Wei Hu (51 yo)

13.7yrs

Görev süresi

CN¥2,634,900

Tazminat

Mr. Wei Hu is Director of Pulike Biological Engineering, Inc. since March 26, 2011 and serves as its Managing Director. Mr. Hu was Deputy General Manager and Non-Independent Director of Pulike Biological E...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wei Hu	MD & Director	13.7yrs	CN¥2.63m	1.22% CN¥ 54.0m
Lian Feng Pei	CFO, Accounting Supervisor & Director	13.7yrs	CN¥1.05m	0.40% CN¥ 17.7m
Yong Jun Song	Deputy GM & Non-Independent Director	13.7yrs	CN¥1.17m	0.88% CN¥ 38.7m
Rui Zhao	Secretary of the Board & Director	8.5yrs	CN¥854.80k	0.0066% CN¥ 288.7k
Xian Sheng Zhang	Independent Director	1.6yrs	CN¥61.10k	Veri yok
Xu Ke Zhang	Chairman of the Board	13.7yrs	CN¥1.19m	31.97% CN¥ 1.4b
Dechao Qin	Vice Chairman	7.5yrs	CN¥2.63m	0.058% CN¥ 2.6m
Chuduan Wang	Independent Director	1.6yrs	CN¥61.10k	Veri yok
Xiaoli Wang	Supervisor	1.6yrs	Veri yok	0.0027% CN¥ 120.3k
Yongchang Cao	Independent Director	1.6yrs	Veri yok	Veri yok
Dongjuan Yuan	Employee Representative Supervisor	1.6yrs	Veri yok	Veri yok

7.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 603566 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Pulike Biological Engineering Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Recent updates

New minor risk - Earnings quality

Less than half of directors are independent

New minor risk - Profit margin trend

Pulike Biological Engineering, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Now 21% undervalued after recent price drop

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Price target decreased by 13% to CN¥16.24

Now 22% undervalued after recent price drop

Price target decreased by 8.3% to CN¥18.56

Pulike Biological Engineering, Inc. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.40 announced

Investor sentiment deteriorates as stock falls 20%

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Investor sentiment improves as stock rises 19%

Now 26% overvalued after recent price rise

Consensus revenue estimates fall by 13%

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.19 in 1Q 2023)

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Pulike Biological Engineering, Inc. to Report Q1, 2024 Results on Apr 26, 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Price target decreased by 8.0% to CN¥25.07

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 15%

Pulike Biological Engineering, Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased by 7.9% to CN¥28.23

New major risk - Earnings quality

Pulike Biological Engineering, Inc. to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 11%

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2022)

Price target decreased to CN¥28.05

Consensus forecasts updated

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.55

Investor sentiment improved over the past week

Price target decreased to CN¥26.37

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.20 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.18 in 1Q 2020)

New 90-day low: CN¥20.02

Full year 2020 earnings released: EPS CN¥0.68 (vs CN¥0.34 in FY 2019)

Revenue and earnings beat expectations

New 90-day low: CN¥20.15

New 90-day low: CN¥21.50

New 90-day low: CN¥23.20

New 90-day low: CN¥23.82

Third quarter earnings released

New 90-day high - CN¥31.00

First half earnings released

New 90-day high - CN¥29.65

Pulike Biological Engineering, Inc. to Report First Half, 2020 Results on Aug 31, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş